Leg Pain After Starting Zepbound (Tirzepatide): Should You Discontinue?
Do not immediately discontinue tirzepatide, but urgently evaluate for peroneal nerve neuropathy (foot drop) if the leg pain involves weakness, numbness, or difficulty lifting your foot—this is a recognized complication of rapid weight loss with tirzepatide that requires prompt medical assessment.
Understanding the Risk: Slimmer's Paralysis
The leg pain you're experiencing after starting Zepbound warrants immediate clinical evaluation because:
- Tirzepatide causes rapid weight loss (mean 20% body weight over 72 weeks) 1, which creates risk for peroneal nerve compression
- Case reports document bilateral foot drop developing 6-8 months after tirzepatide initiation due to "slimmer's paralysis"—peroneal nerve neuropathy from rapid weight loss 2
- This adverse event is not mentioned in the drug labeling but represents an emerging safety concern 3
Immediate Assessment Required
Red Flag Symptoms (Require Urgent Evaluation):
- Foot drop (difficulty lifting the front of your foot)
- Numbness or tingling along the outer leg or top of foot
- Weakness when walking or climbing stairs
- Bilateral symptoms (both legs affected)
If These Are Present:
- Stop tirzepatide immediately and contact your prescriber
- Obtain neurological examination within 24-48 hours
- Consider nerve conduction studies if foot drop confirmed 2
If Pain Without Neurological Symptoms
Other Tirzepatide-Associated Musculoskeletal Concerns:
- Rhabdomyolysis (muscle breakdown) has been reported with tirzepatide 4
- Check for: severe muscle pain, dark urine, extreme weakness
- If present: obtain urgent creatine kinase (CK) level and discontinue drug
Common Adverse Events Timeline:
Most tirzepatide adverse events occur within 1-6 months of initiation 3, with the highest incidence at the 2.5-5 mg dose range 3
Decision Algorithm
If leg pain + neurological symptoms (weakness/numbness/foot drop): → STOP tirzepatide → Urgent neurology evaluation
If leg pain + severe muscle pain + dark urine: → STOP tirzepatide → Check CK level immediately → Rule out rhabdomyolysis 4
If isolated leg pain without above features: → Continue tirzepatide with close monitoring → Document pain characteristics, timing, severity → Reassess in 1-2 weeks → Consider dose reduction if pain worsens
Critical Monitoring Points
Given that 74.42% of tirzepatide adverse events are assessed as "probable" causality 3, enhanced monitoring is warranted:
- Weekly assessment of neurological symptoms during first 3 months
- Monthly weight tracking (rapid loss >2-3 kg/week increases neuropathy risk)
- Monitor for gastrointestinal symptoms (most common adverse events at 39-49% depending on dose) 5
Important Caveats
Dosing Errors Are Common:
- Incorrect dose administration is the #1 reported adverse event, increasing 8-fold from 2022-2024 6
- Verify you're using correct dose and injection technique
- Injection site pain affects thousands of patients 6
When Discontinuation Is Appropriate:
Among reported cases, 15 patients discontinued tirzepatide due to adverse events, while only 3 continued 3. Drug discontinuation rates are highest (10%) with the 15 mg dose 5.
Balance Risk vs. Benefit:
Tirzepatide offers substantial benefits for cardiovascular risk reduction and weight loss 1, but risks versus benefits should be discussed in detail before continuing, especially with emerging adverse events 4.
Bottom Line
The leg pain timing after tirzepatide initiation is concerning for an emerging adverse event pattern. While not all leg pain requires discontinuation, the documented cases of peroneal neuropathy 2 and rhabdomyolysis 4 mandate urgent evaluation to rule out serious complications. If neurological examination is normal and CK is not elevated, continuation with close monitoring is reasonable, but any progression of symptoms should prompt immediate discontinuation.